Literature DB >> 26182154

Development of a hepatocellular carcinoma in a chronic hepatitis C patient 18 years after achieving a sustained virological response to interferon therapy: case report and literature review.

Masaya Saito1, Yasushi Seo1, Yoshihiko Yano1,2, Akira Miki1, Yukiko Morinaga3, Tomoo Itoh3, Masaru Yoshida1,4, Takeshi Azuma5.   

Abstract

We report on a chronic hepatitis C patient who developed hepatocellular carcinoma (HCC) 18 years after achieving a sustained virological response (SVR) to interferon therapy. We also review other reports of patients who developed HCC a long time after interferon therapy. The patient was a 67-year-old man with chronic hepatitis C who achieved an SVR to interferon therapy at the age of 49 years in 1992. Eighteen years later, however, a tumor measuring 19 mm in diameter in segment 7 of the liver was found by abdominal ultrasound. The tumor had a typical HCC enhancement pattern by dynamic computed tomography. A moderately to poorly differentiated HCC was confirmed by fine-needle aspiration biopsy. Fibrosis and inflammation in the liver parenchyma improved pathologically from F3A2 to F2A1 according to the New Inuyama Classification. Liver steatosis remained after achieving an SVR and the serum alanine aminotransferase level was persistently slightly elevated. The HCC was treated by transcatheter arterial chemoembolization combined with radiofrequency ablation. Patients with chronic hepatitis C who have achieved an SVR to interferon therapy, and those who have risk factors for the development of HCC, such as being male, of advanced age (<50 years is rare), or with progressive liver fibrosis and steatosis as a hepatic manifestation of metabolic syndrome, should undergo careful long-term follow-up.

Entities:  

Keywords:  Chronic hepatitis C; Hepatocellular carcinoma; Interferon therapy; Sustained virological response

Year:  2012        PMID: 26182154     DOI: 10.1007/s12328-012-0284-7

Source DB:  PubMed          Journal:  Clin J Gastroenterol        ISSN: 1865-7265


  29 in total

1.  Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy.

Authors:  Akiko Makiyama; Yoshito Itoh; Akinori Kasahara; Yasuharu Imai; Sumio Kawata; Kentaro Yoshioka; Hirohito Tsubouchi; Kendo Kiyosawa; Shinichi Kakumu; Kiwamu Okita; Norio Hayashi; Takeshi Okanoue
Journal:  Cancer       Date:  2004-10-01       Impact factor: 6.860

2.  Relationship between response to previous interferon therapy and postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma.

Authors:  Takahiro Uenishi; Shoji Kubo; Kazuhiro Hirohashi; Hiromu Tanaka; Taichi Shuto; Takatsugu Yamamoto; Akihiro Tamori; Seikan Hai; Hiroaki Kinoshita; Shuhei Nishiguchi
Journal:  Hepatol Res       Date:  2002-12       Impact factor: 4.288

3.  Hepatitis B virus DNA integration in hepatocellular carcinoma after interferon-induced disappearance of hepatitis C virus.

Authors:  Akihiro Tamori; Shuhei Nishiguchi; Susumu Shiomi; Takehiro Hayashi; Sawako Kobayashi; Daiki Habu; Tadashi Takeda; Shuichi Seki; Kazuhiro Hirohashi; Hiromu Tanaka; Shoji Kubo
Journal:  Am J Gastroenterol       Date:  2005-08       Impact factor: 10.864

4.  Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis.

Authors:  K Ikeda; S Saitoh; Y Arase; K Chayama; Y Suzuki; M Kobayashi; A Tsubota; I Nakamura; N Murashima; H Kumada; M Kawanishi
Journal:  Hepatology       Date:  1999-04       Impact factor: 17.425

5.  Hepatic gene expression profiles associated with fibrosis progression and hepatocarcinogenesis in hepatitis C patients.

Authors:  Run-Xuan Shao; Yujin Hoshida; Motoyuki Otsuka; Naoya Kato; Ryosuke Tateishi; Takuma Teratani; Shuichiro Shiina; Hiroyoshi Taniguchi; Masaru Moriyama; Takao Kawabe; Masao Omata
Journal:  World J Gastroenterol       Date:  2005-04-07       Impact factor: 5.742

6.  Fibrosis in non-cancerous tissue is the unique prognostic factor for primary hepatocellular carcinoma without hepatitis B or C viral infection.

Authors:  Yoshito Tomimaru; Yo Sasaki; Terumasa Yamada; Hidetoshi Eguchi; Hiroaki Ohigashi; Osamu Ishikawa; Shingi Imaoka
Journal:  World J Surg       Date:  2006-09       Impact factor: 3.352

7.  Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database.

Authors:  Tania M Welzel; Barry I Graubard; Stefan Zeuzem; Hashem B El-Serag; Jessica A Davila; Katherine A McGlynn
Journal:  Hepatology       Date:  2011-06-30       Impact factor: 17.425

8.  Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.

Authors:  M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht
Journal:  Lancet       Date:  2001-09-22       Impact factor: 79.321

9.  Case report: development of hepatocellular carcinoma in a patient with chronic hepatitis C infection after a complete and sustained response to interferon-alpha.

Authors:  N Hirashima; M Mizokami; E Orito; T Koide; I Itazu; K Kumada; K Sakakibara; H Kano; J Y Lau
Journal:  J Gastroenterol Hepatol       Date:  1996-10       Impact factor: 4.029

10.  Differences in molecular alterations of hepatocellular carcinoma between patients with a sustained virological response and those with hepatitis C virus infection.

Authors:  Takehiro Hayashi; Akihiro Tamori; Manabu Nishikawa; Hiroyasu Morikawa; Masaru Enomoto; Hiroki Sakaguchi; Daiki Habu; Norifumi Kawada; Shoji Kubo; Shuhei Nishiguchi; Susumu Shiomi
Journal:  Liver Int       Date:  2008-05-19       Impact factor: 5.828

View more
  2 in total

Review 1.  Occurrence of hepatocellular carcinoma 24 years after successful interferon therapy in a patient with chronic hepatitis C: a case report.

Authors:  Yuichi Yoshida; Miki Yonezawa; Takuya Okamoto; Yudai Fujiwara; Akiko Suzuki; Yuji Suzuki; Kei Endo; Keisuke Kakisaka; Takayoshi Oikawa; Hidekatsu Kuroda; Akio Miyasaka; Yasuhiro Takikawa
Journal:  Clin J Gastroenterol       Date:  2018-10-19

2.  Two Cases of Hepatocellular Carcinoma Arising Over 20 Years after a Sustained Virologic Response Following Interferon Therapy for Chronic Hepatitis C.

Authors:  Kazuhide Takata; Fuminori Ishii; Yotaro Uchida; Hiromi Fukuda; Ryo Yamauchi; Kaoru Umeda; Naoaki Tsuchiya; Takashi Tanaka; Keiji Yokoyama; Daisuke Morihara; Yasuaki Takeyama; Satoshi Shakado; Shotaro Sakisaka; Fumihito Hirai
Journal:  Intern Med       Date:  2020-04-30       Impact factor: 1.271

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.